Rinvoq® (Upadacitinib Extended-Release Tablets) Receives Fourth Indication Approval in China for Moderate to Severe Active Ulcerative Colitis

Recently, AbbVie announced that the fourth indication UC of its immunology innovation drug RINVOQ® (Upadacitinib Extended-Release Tablets) has been approved in China.

Source of the image: AbbVie Official WeChat

Editor: Pea Shooter

Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding content, copyright, or other matters, please leave a message on this platform, and we will address it promptly.